Idiopathic Pulmonary Fibrosis Treatment Market Report | Size, Share & Growth Outlook 2030

[Research Report] The idiopathic pulmonary fibrosis treatment market size is projected to surge from US$ 4,360.87 million in 2022 to US$ 10,784.07 million by 2030; the market is estimated to grow at a CAGR of 12.0% during 2022–2030.

Analyst Perspective: 

Idiopathic pulmonary fibrosis is a chronic condition that affects the tissue surrounding the alveoli in the lungs. It develops when lung tissues become stiff and thick for unknown reasons, and these changes result in permanent scarring in the lungs over time, which makes breathing difficult among patients. Currently, there is no precise cure for idiopathic pulmonary fibrosis. Treatments such as pulmonary rehabilitation, medicines, and surgical procedures slow down lung damage and help enhance the quality of patients’ lives.

The growing prevalence of idiopathic pulmonary fibrosis and an increasing number of people smoking cigarettes propel the demand for effective treatment drugs in the coming years. Ongoing research work to introduce effective drugs for idiopathic pulmonary fibrosis treatment is likely to further benefit the market in the future. Currently, healthcare spending has been increasing in both developed and emerging markets, which is expected to encourage manufacturers in this market to consolidate their efforts focused on developing new and innovative products.

Market Overview:

Fibrosis is the deposition of connective tissue that occurs as part of the normal healing process or the deposition of excess tissue that occurs as a pathological process. Idiopathic pulmonary fibrosis affects connective tissue in the lungs and alveoli (air sacs in the lungs). The condition may cause shortness of breath among people while performing their routine tasks, which aren’t tiresome for people in good health. The growth of the idiopathic pulmonary fibrosis treatment market is attributed to the growing burden of fibrotic conditions and an upsurge in the number of people smoking cigarettes. The rapid-paced research and development activities, leading to technological advancements in treatments, are expected to provide growth opportunities for the idiopathic pulmonary fibrosis treatment market in the coming years.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Idiopathic Pulmonary Fibrosis Treatment Market: Strategic Insights

Idiopathic Pulmonary Fibrosis Treatment Market

• 
  CAGR (2022 - 2030)

  12.0%
• Market Size 2022
  US$ 4,360.87 Million
• Market Size 2030
  US$ 10,784.07 Million

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• C H Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• F Hoffmann La Roche Ltd
• AstraZeneca
• Shionogi and Co Ltd
• Cipla Ltd
• Others

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Drug Type

• Nintedanib
• Pirfenidone

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies and Online Pharmacies

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Driver:

Growing Burden of Idiopathic Pulmonary Fibrosis Drive Idiopathic Pulmonary Fibrosis Treatment Market

According to data from the American Lung Association, updated in November 2022, approximately 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed in the US each year. Symptoms of this condition are more noticeable in patients of age 50–70. According to an article published in the British Medical Journal in September 2022, the estimated prevalence of idiopathic pulmonary fibrosis in specialized care units in 2021 was 36.0 per 100,000. The number of patients suffering from idiopathic pulmonary fibrosis is increasing worldwide due to common risk factors such as aging, obesity, high blood pressure (hypertension), or family history, and the condition is becoming a significant socioeconomic burden for economies. Therefore, the increasing number of patients with idiopathic pulmonary fibrosis propels bolsters the fibrotic disease treatment market growth. 

Segmental Analysis:

Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022–2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases. 

Regional Analysis: 

North America dominates the global idiopathic pulmonary fibrosis treatment market. The market in North America was valued at US$ 2,362.95 million in 2022 and is projected to reach US$ 5,527.28 million by 2030; it is expected to register a CAGR of 11.2% during 2022–2030. The North American idiopathic pulmonary fibrosis treatment market is segmented into the US, Canada, and Mexico. The increasing burden of idiopathic pulmonary fibrosis and technological advancements in treatments benefit the idiopathic pulmonary fibrosis treatment market in North America. Product launches and strategic initiatives by key market players also contribute to the market growth. With the growing number of research and development activities to treat idiopathic pulmonary fibrosis, improved drugs are being introduced into the market, which results in better access to medicines for a wider patient pool. Further, extensive FDA approvals in the region encourage companies to launch technologically sophisticated products.

With the rising prevalence of idiopathic pulmonary fibrosis and high healthcare expenditure, Europe holds the second largest share in the global fibrotic disease treatment market. Germany is expected to dominate the European idiopathic pulmonary fibrosis treatment market due to better access to technologically advanced products and services in the healthcare sector.

Asia Pacific is expected to register the fastest CAGR in the global idiopathic pulmonary fibrosis treatment market during 2022–2030. The projected market growth can be credited to the widespread acceptance and adoption of cutting-edge technologies that produce accurate results in a significantly shorter time.Healthcare industries across the region are leveraging innovations in artificial intelligence, automation, and digital transformation, driving efficiency and productivity medical professionals. The ongoing transformation in various industries strengthens businesses and economies across Asia Pacific, allowing them to position themselves as the fastest developing hub with a dynamic and forward-thinking approach to sustainable progress.

Key Player Analysis:

The idiopathic pulmonary fibrosis treatment market analysis is based on key players such as Genentech, Inc. and Boehringer Ingelheim International GmbH.

Idiopathic Pulmonary Fibrosis Treatment Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Recent Developments: 

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the idiopathic pulmonary fibrosis treatment market. A few recent developments are listed below:   

• In May 2023, Boehringer Ingelheim initiated the clinical development of BI 765423, a breakthrough IL-11 inhibitor antibody. The Phase 1 study (NCT05658107) focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteer subjects. Preclinical studies have shown promising results of this anti-IL-11 drug in inhibiting and potentially reversing fibrosis in various fibrotic cases.
• In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550. BI 1015550 is an experimental phosphodiesterase 4B (PDE4B) inhibitor discovered for treating individuals suffering from idiopathic pulmonary fibrosis. The study is a part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF in patients with idiopathic pulmonary fibrosis and FIBRONEER-ILD in adults with other progressive fibrosing interstitial lung diseases (ILDs).
• In September 2022, Bellerophon Therapeutics, Inc. announced that the FDA accepted the trial size reduction application for its current REBUILD Phase 3 registration trial of INOpulse, indicated for the treatment of fibrotic interstitial lung disease (LD). 
• In May 2022, ArisGlobal, a global leader in drug safety solutions, acquired Boehringer Ingelheim's BRASS digital innovation. The acquisition enabled the former to enhance its LifeSphere technology platform by integrating BRASS into LifeSphere Clarity. This integration has contributed to the advancement of pharmacovigilance and patient safety across the industry. Moreover, ArisGlobal has expanded its clinical diagnostics business presence in various regions worldwide, consolidating its global position.
• In March 2022, Bristol Myers Squibb, a leading pharmaceutical company, announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition has significantly strengthened Bristol Myers Squibb's global presence in the pharmaceutical market, allowing it to be more proactive in bringing innovations to the industry while expanding its portfolio of life-saving therapies and treatments.